281 related articles for article (PubMed ID: 31664185)
1. Letermovir prophylaxis through day 100 post transplant is safe and effective compared with alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation.
Sharma P; Gakhar N; MacDonald J; Abidi MZ; Benamu E; Bajrovic V; Purev E; Haverkos BM; Tobin J; Kaiser J; Chase S; Miller M; Weinberg A; Gutman JA
Bone Marrow Transplant; 2020 Apr; 55(4):780-786. PubMed ID: 31664185
[TBL] [Abstract][Full Text] [Related]
2. Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients.
Hill JA; Zamora D; Xie H; Thur LA; Delaney C; Dahlberg A; Pergam SA; Leisenring WM; Boeckh M; Milano F
Blood Adv; 2021 Aug; 5(16):3113-3119. PubMed ID: 34402885
[TBL] [Abstract][Full Text] [Related]
3. Letermovir Prophylaxis Decreases Burden of Cytomegalovirus (CMV) in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant.
Johnsrud JJ; Nguyen IT; Domingo W; Narasimhan B; Efron B; Brown JW
Biol Blood Marrow Transplant; 2020 Oct; 26(10):1963-1970. PubMed ID: 32653623
[TBL] [Abstract][Full Text] [Related]
4. Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality.
Liu LW; Yn A; Gao F; Olson M; Crain M; Abboud R; Westervelt P; Abboud C; Vij R; Stockerl-Goldstein K; Pusic I; Cashen AF; Schroeder MA
Transplant Cell Ther; 2022 Aug; 28(8):510.e1-510.e9. PubMed ID: 35598841
[TBL] [Abstract][Full Text] [Related]
5. Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide.
Freyer CW; Carulli A; Gier S; Ganetsky A; Timlin C; Schuster M; Babushok D; Frey NV; Gill SI; Hexner EO; Luger SM; Mangan JK; Martin ME; McCurdy SR; Perl AE; Porter DL; Pratz K; Smith J; Stadtmauer EA; Loren AW
Leuk Lymphoma; 2022 Aug; 63(8):1925-1933. PubMed ID: 35188052
[TBL] [Abstract][Full Text] [Related]
6. Letermovir prophylaxis for cytomegalovirus reactivation in allogeneic hematopoietic cell transplant recipients: Single center Canadian data.
Pang I; Chen P; Trinh GV; Remberger M; Novitzky-Basso I; Gerbitz A; Kim DD; Kumar R; Lam W; Law AD; Lipton JH; Viswabandya A; Pasic I; Mattsson J; Michelis FV
Eur J Haematol; 2024 Feb; 112(2):301-309. PubMed ID: 37830403
[TBL] [Abstract][Full Text] [Related]
7. Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
Anderson A; Raja M; Vazquez N; Morris M; Komanduri K; Camargo J
Clin Transplant; 2020 Jul; 34(7):e13866. PubMed ID: 32242979
[TBL] [Abstract][Full Text] [Related]
8. Comparative Efficacy and Safety of Different Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.
Gagelmann N; Ljungman P; Styczynski J; Kröger N
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2101-2109. PubMed ID: 29777868
[TBL] [Abstract][Full Text] [Related]
9. Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from the French Compassionate Program.
Robin C; Thiebaut A; Alain S; Sicre de Fontbrune F; Berceanu A; D'Aveni M; Ceballos P; Redjoul R; Nguyen-Quoc S; Bénard N; Pahlavan-Grumel G; Cordonnier C
Biol Blood Marrow Transplant; 2020 May; 26(5):978-984. PubMed ID: 32035273
[TBL] [Abstract][Full Text] [Related]
10. Extended letermovir administration, beyond day 100, is effective for CMV prophylaxis in patients with graft versus host disease.
Bansal R; Gordillo CA; Abramova R; Assal A; Mapara MY; Pereira MR; Reshef R
Transpl Infect Dis; 2021 Apr; 23(2):e13487. PubMed ID: 33034124
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus Immune reconstitution in cord blood transplant recipients on letermovir prophylaxis.
Abidi MZ; Molina KC; Garth K; Gutman JA; Weinberg A
Transpl Infect Dis; 2023 Oct; 25(5):e14104. PubMed ID: 37436771
[TBL] [Abstract][Full Text] [Related]
12. Letermovir Prophylaxis for CMV Reactivation in Allogeneic Stem Cell Recipients: A Retrospective Single Center Analysis.
Koch K; Osswald L; Miller I; Braitsch K; Götze K; Bassermann F; Herhaus P; Verbeek M
Anticancer Res; 2022 Nov; 42(11):5431-5441. PubMed ID: 36288861
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxis.
Saullo JL; Baker AW; Snyder LD; Reynolds JM; Zaffiri L; Eichenberger EM; Ferrari A; Steinbrink JM; Maziarz EK; Bacchus M; Berry H; Kakoullis SA; Wolfe CR
J Heart Lung Transplant; 2022 Apr; 41(4):508-515. PubMed ID: 35031206
[TBL] [Abstract][Full Text] [Related]
14. Letermovir Prophylaxis for Cytomegalovirus Infection in Children After Hematopoietic Cell Transplantation.
Richert-Przygonska M; Jaremek K; Debski R; Konieczek J; Lecka M; Dziedzic M; Bogiel T; Styczynski J; Czyzewski K
Anticancer Res; 2022 Jul; 42(7):3607-3612. PubMed ID: 35790275
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus breakthrough and resistance during letermovir prophylaxis.
Perchetti GA; Biernacki MA; Xie H; Castor J; Joncas-Schronce L; Ueda Oshima M; Kim Y; Jerome KR; Sandmaier BM; Martin PJ; Boeckh M; Greninger AL; Zamora D
Bone Marrow Transplant; 2023 Apr; 58(4):430-436. PubMed ID: 36693927
[TBL] [Abstract][Full Text] [Related]
16. Impact of letermovir prophylaxis in CMV reactivation and disease after allogenic hematopoietic cell transplantation: a real-world, observational study.
Brusosa M; Ruiz S; Monge I; Solano MT; Rosiñol L; Esteve J; Carreras E; Marcos MÁ; Riu G; Carcelero E; Martinez C; Fernández-Avilés F; Rovira M; Suárez-Lledó M; Salas MQ
Ann Hematol; 2024 Feb; 103(2):609-621. PubMed ID: 37957371
[TBL] [Abstract][Full Text] [Related]
17. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
Marty FM; Ljungman P; Chemaly RF; Maertens J; Dadwal SS; Duarte RF; Haider S; Ullmann AJ; Katayama Y; Brown J; Mullane KM; Boeckh M; Blumberg EA; Einsele H; Snydman DR; Kanda Y; DiNubile MJ; Teal VL; Wan H; Murata Y; Kartsonis NA; Leavitt RY; Badshah C
N Engl J Med; 2017 Dec; 377(25):2433-2444. PubMed ID: 29211658
[TBL] [Abstract][Full Text] [Related]
18. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants.
Ljungman P; de La Camara R; Milpied N; Volin L; Russell CA; Crisp A; Webster A;
Blood; 2002 Apr; 99(8):3050-6. PubMed ID: 11929799
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic analysis driven letermovir dosing in pediatric hematopoietic cell transplantation patients with resistant CMV disease.
Pai VB; Tansmore J; Song E
Pediatr Transplant; 2024 Feb; 28(1):e14580. PubMed ID: 37466088
[TBL] [Abstract][Full Text] [Related]
20. [Clinical analysis of the usefulness of letermovir for prevention of cytomegalovirus infection after haploidentical hematopoietic stem cell transplantation].
Ma R; He Y; Wang HF; Bai L; Han W; Cheng YF; Liu KY; Xu LP; Zhang XH; Wang Y; Zhang YY; Wang FR; Mo XD; Yan CH; Huang XJ; Sun YQ
Zhonghua Nei Ke Za Zhi; 2023 Jul; 62(7):826-832. PubMed ID: 37394853
[No Abstract] [Full Text] [Related]
[Next] [New Search]
